Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

358
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
358
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-recanalization administration of rapamycin improves functional outcome and reduces infarct size in a rat model of ischemic stroke.

Neuroprotection (Chichester, England)·2026
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Environmental footprint of peritoneal dialysis in Europe: a comparative life cycle assessment across four European centres.

Clinical kidney journal·2026
Same author

Greener dialysis in practice: life cycle assessment of sustainable practice changes in haemodialysis care.

BMC nephrology·2026
Same author

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal for immunotherapy of cancer·2026
Same author

The NHS and industry partnerships: risky alliances.

BMJ (Clinical research ed.)·2026
Same journal

Patient-derived organoids in hematologic malignancies: Fidelity and translation beyond animals.

Trends in cancer·2026
Same journal

Precision neuro-oncology for children: Time to gear up!

Trends in cancer·2026
Same journal

Multi-omics analysis of extracellular vesicle cargo in cancer.

Trends in cancer·2026
Same journal

An immunological panacea for cancer-related cachexia.

Trends in cancer·2026
Same journal

Beyond one gene, one target: Next-generation precision oncology.

Trends in cancer·2026
Same journal

Horizontal mitochondrial transfer and the tug-of-war between cancer cells and immune cells.

Trends in cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

717

Lifileucel: the first cellular therapy approved for solid tumours.

Max Julve1, Mark P Lythgoe2, James Larkin1

  • 1Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Trends in Cancer
|May 9, 2024
PubMed
Summary
This summary is machine-generated.

The US Food and Drug Administration (FDA) approved lifileucel, a cellular therapy for advanced melanoma. This marks a significant milestone as the first cell therapy for solid tumors, addressing implementation challenges.

Keywords:
FDA approvalcell therapyimmunotherapylifileucelmelanomatumour infiltrating lymphocyte therapy

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

493

Related Experiment Videos

Last Updated: Jun 26, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

717
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

493

Area of Science:

  • Oncology
  • Cellular Therapy
  • Immunotherapy

Background:

  • Advanced melanoma presents significant treatment challenges.
  • The development of novel cancer therapies is crucial.
  • Cellular therapies offer a promising new avenue for solid tumors.

Purpose of the Study:

  • To summarize the FDA approval of lifileucel for advanced melanoma.
  • To examine the regulatory pathway for this novel cellular therapy.
  • To evaluate challenges in implementing advanced 'living' therapies.

Main Methods:

  • Review of FDA approval documentation for lifileucel.
  • Analysis of the regulatory landscape for cellular therapies.
  • Discussion of clinical implementation strategies and challenges.

Main Results:

  • Lifileucel is the first cellular therapy approved by the FDA for a solid cancer.
  • The approval signifies a breakthrough in cancer treatment.
  • Regulatory pathways for advanced therapies are evolving.

Conclusions:

  • The approval of lifileucel is a landmark achievement in oncology.
  • Effective implementation requires addressing logistical and clinical challenges.
  • This therapy paves the way for future cellular treatments in solid tumors.